Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.76 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.76 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166899 | 1.00 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6158522 | 1.00 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4374909 | 0.94 | PTGER4 (0.68) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14268653 | 0.94 | PTGER4 (0.68) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2209602 | 0.94 | PTGER4 (0.68) | PTGER4PTGER3PTGER2 | |
| SCHEMBL13766272 | 0.93 | PTGER4 (0.67) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14307456 | 0.92 | PTGER4 (0.66) | PTGER4PTGER3PTGER2 | |
| SCHEMBL13204801 | 0.90 | PTGER4 (0.63) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4994629 | 0.89 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4994622 | 0.89 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1132086-B1 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1490055-A1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF LIVER FAILURE, LOSS OF PATENCY OF THE DUCTUS ARTERIOSUS, GLAUCOMA OR OCULAR HYPERTENSION | Pfizer Products Inc. (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003077908-A1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF LIVER FAILURE, LOSS OF PATENCY OF THE DUCTUS ARTERIOSUS, GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | claimed |
| US-20030176479-A1 | Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | CAMERON KIMBERLY O (US) | 2003-09-18 | — | — | US | claimed |
| US-6610719-B2 | 5-(3-hydroxy-4-phenyl-but-1-enyl)-1-(6-(1H-tetrazol-5-yl)-hexyl) -pyrrolidin-2-one, for example | PFIZER INC. | 2003-08-26 | — | — | US | claimed |
| US-20010041729-A1 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | PARALKAR VISHWAS M (US) | 2001-11-15 | — | — | US | claimed |
| EP-1132086-A2 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | Pfizer Products Inc. (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1132086-B1 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1490055-A1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF LIVER FAILURE, LOSS OF PATENCY OF THE DUCTUS ARTERIOSUS, GLAUCOMA OR OCULAR HYPERTENSION | Pfizer Products Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6737437-B2 | FOR EXAMPLE, 7-(2S-(3R-HYDROXY-4-PHENYLBUTYL)-5-OXOPYRROLIDIN -1-YL)HEPTANOIC ACID; PROMOTING BONE READSORPTION; BONE LOSS, FRACTURES, AND DEFECTS; FRAILTY; CHILDHOOD IDIOPATHIC BONE LOSS; ALVEOLAR BONE LOSS, OSTEOTOMY; GUM DISEASE; PROSTHETICS | PFIZER INC. | 2004-05-18 | — | — | US | disclosed |
| US-6642266-B2 | Therapy of condition which presents with low bone mass in a mammal comprising administering to mammal an EP4 (prostaglandins) receptor selective agonist or prodrug | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| WO-2003077908-A1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF LIVER FAILURE, LOSS OF PATENCY OF THE DUCTUS ARTERIOSUS, GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1110949-B1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PROD INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | CAMERON KIMBERLY O (US) | 2001-12-27 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| US-20010041729-A1 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | PARALKAR VISHWAS M (US) | 2001-11-15 | — | — | US | disclosed |
| EP-1132086-A2 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | Pfizer Products Inc. (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1121939-A2 | Treatment of osteoporosis with EP2/EP4 receptor selective agonists | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041729-A1 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885PTGER2 4/4885 |
| US-20030176479-A1 | Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | PTGER4, PTGER2, PTGER1 | PTGER4 1/4885PTGER3 4/4885PTGER2 2/4885 |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | PTGER2, PTGER1, PTGER4 | PTGER4 3/4885PTGER3 4/4885PTGER2 1/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.